We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Purespring Therapeutics, PS-003, Alport Syndrome, X-Linked Alport Syndrome, Gene Therapy, Kidney Disease, Renal Disease, COL4A5, COL4A3, COL4A4, GlomThera Platform,

Advertisement

cGxPJobs Banner

Purespring Therapeutics Advances PS-003 Kidney-Targeted Gene Therapy Towards Clinical Development for X-Linked Alport Syndrome

LONDON, UK — October 27, 2026 Purespring Therapeutics, a precision nephrology company developing genetically targeted therapies for kidney diseases,...

By cGxPwire Editor
October 28, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

Bio-Pharma

Genmab Reports Positive Phase 3 Petosemtamab Combination Results in Head and Neck Cancer
October 29, 2026
02

Bio-Pharma

HUTCHMED Receives FDA Orphan Drug Designation for Sovleplenib in Immune Thrombocytopenia
October 29, 2026
03

Bio-Pharma

Idorsia and Nxera Pharma Expand Partnership as Phase 3 Lucerastat Study Begins
October 29, 2026
04

Bio-Pharma

Monte Rosa Therapeutics Earns $37.5M Milestone as Novartis Starts Second Phase 2 Trial of MRT-6160
October 29, 2026
05

Bio-Pharma

Roche Launches VENTANA BAP1 Test to Improve Differential Diagnosis of Mesothelioma
October 29, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website